MINERALYS THERAPEUTICS, INC. Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss
MINERALYS THERAPEUTICS, INC. (MLYS) had Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss of $535.58 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets
us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss · last filed 2026-08-11
- 2026-06-30: Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss $535.58M.
- 2025-12-31: Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss $493.66M.
- 2025-09-30: Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss $480.48M.
- 2025-06-30: Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss $228.09M.
| Period end | Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss |
|---|---|
| 2026-06-30 | $535.58M 10-Q · filed 2026-08-11 |
| 2025-12-31 | $493.66M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $480.48M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $228.09M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $217.77M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $113.92M 10-K · filed 2026-03-12 |
| 2024-09-30 | $166.33M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $243.26M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $248.15M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $189.75M 10-K · filed 2025-02-12 |
| 2023-09-30 | $179.60M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $181.60M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $163.50M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $22.41M 10-K · filed 2024-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |